Reta

🔬 Retatrutide — Research Peptide

Retatrutide (LY 3437943) is an investigational research peptide and a triple-agonist that activates the GLP-1, GIP, and glucagon (GCG) receptors. It is studied for its potential effects on weight management, metabolic regulation, and energy balance in preclinical and clinical research settings.

Research Focus & Mechanism

• GLP-1 receptor activation: Investigated for improving glycemic control and regulating appetite

• GIP receptor activation: Studied for enhancing insulin secretion and supporting glucose metabolism

• Glucagon receptor activation: Explored for increasing energy expenditure, lipolysis, and potential effects on liver fat metabolism

• Slows gastric emptying and reduces caloric intake in research models, contributing to weight reduction studies

Research Insights

• Phase 2 trials in humans have shown significant body-weight reduction in obesity research models (up to ~24% over 48 weeks in highest dose groups)

• Explored for potential improvements in blood glucose, lipid profiles, and metabolic biomarkers

• Being investigated in combination or comparison studies with other peptides for enhanced efficacy in weight and metabolic research

⚠️ Disclaimer:

Retatrutide is intended for laboratory research purposes only.

It is not approved for human use, consumption, or medical treatment.

FOR RESEARCH PURPOSES ONLY

LYOPHILIZED POWDER VIAL

WILL REQUIRE RECONSTITUTION WITH BACTERIOSTATIC WATER, SOLD SEPARATELY